INSULIN ASPART (in'su-lyn)
NovoLog Classifications: hormone; antidiabetic agent; insulin, rapid-acting; Therapeutic: antidiabetic; insulin rapid-acting Prototype: Insulin injection Pregnancy Category: C
|
Availability
100 U/mL injection
Action
A recombinant insulin analog that is more rapidly absorbed than human insulin, with a more rapid onset and shorter duration
than regular human insulin.
Therapeutic Effect
Provides better blood glucose control than regular human insulin when given before a meal.
Uses
Treatment of diabetes mellitus.
Contraindications
Systemic allergic reactions; history of allergic reactions to insulin; hypoglycemia; pregnancy (category C).
Cautious Use
Fever, hyperthyroidism, surgery or trauma; decreased insulin requirements due to diarrhea, nausea, or vomiting, malabsorption;
renal or hepatic impairment, hypokalemia.
Route & Dosage
Diabetes Adult: SC 0.250.7 units/kg/d injected 510 min before each meal
|
Administration
Subcutaneous
- Note: Must give 510 min before a meal.
- Draw up insulin aspart first when mixing with NPH insulin. Give injection immediately after it is mixed. Do not give NPH
mixture by IV.
- Store refrigerated at 2°8° C (36°46° F); may be stored at room temperature, 15°30°
C (59°86° F) for up to 28 d. Do not expose to excessive heat or sunlight, and do not freeze.
Adverse Effects (≥1%)
Body as a Whole: Allergic reactions.
Endocrine: Hypoglycemia, hypokalemia.
Skin: Injection site reaction, lipodystrophy, pruritus, rash.
Interactions
Drug: oral antidiabetic agents,
ace inhibitors,
disopyramide, fluoxetine, mao inhibitors,
propoxyphene, salicylates,
sulfonamide antibiotics,
octreotide may enhance hypoglycemia;
corticosteroids,
niacin, danazol, diuretics,
sympathomimetic agents,
phenothiazines,
thyroid hormones,
estrogens,
progestogens,
isoniazid, somatropin my decrease hypoglycemic effects;
beta-blockers,
clonidine, lithium, alcohol may either potentiate or weaken effects of insulin;
pentamidine may cause
hypoglycemia followed by hyperglycemia.
Herbal: Garlic, ginseng may potentiate hypoglycemic effects.
Pharmacokinetics
Absorption: Rapidly absorbed from SC injection site.
Onset: 15 min.
Peak: 13 h.
Duration: 35 h.
Distribution: Low protein binding.
Metabolism: In liver with some
metabolism in the kidneys.
Half-Life: 81 min.
Nursing Implications
Assessment & Drug Effects
- Monitor for S&S of hypoglycemia (see Appendix F). Initial hypoglycemic response begins within 15 min and peaks 4590
min after injection.
- Lab tests: Periodically monitor fasting blood glucose and HbA1C.
- Withhold drug and notify physician if patient is hypokalemic.
Patient & Family Education
- Do not inject into areas with redness, swelling, itching, or dimpling.
- Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop, and seek
medical assistance.
- Check blood sugar as prescribed, especially postprandial values; notify physician of fasting blood glucose <80 and >120
mg/dL.
- Notify the physician of any of the following: Fever, infection, trauma, diarrhea, nausea or vomiting. Dosage adjustment may
be needed.
- Do not take any other medication unless approved by the physician.